Author Correction: Identification of KIFC1 as an independent prognostic marker in renal clear cell carcinoma correlates with tumor proliferation and immune infiltration

Bin Du, Jia Wang, Jinping Zheng, Jing Huo, Pu WangScientific 2025 · DOI · OpenAlex

Abstract

Due to an error during figure assembly, in Figure 8A two cells in the stage "telophase I" were selected. One exemplary cell has been replaced with a "telophase II" stage cell.

Introduction

Renal clear cell carcinoma (ccRCC) represents the most prevalent and aggressive form of kidney cancer. Identifying reliable prognostic biomarkers is essential for tailoring therapeutic strategies and predicting patient outcomes. Recent research has highlighted KIFC1 (Kinesin Family Member C1) as a critical player in tumor progression. KIFC1 is a minus-end-directed motor protein that enables cancer cells to survive "centrosome amplification"—a condition where cells possess excess structural hubs. By clustering these hubs, KIFC1 prevents mitotic catastrophe, allowing malignant cells to proliferate. This paper details a correction to the spatial mapping of KIFC1-interacting proteins and its mitotic localization.

Methods

To elucidate the functional landscape of KIFC1 in ccRCC, researchers utilized a multi-omic approach:

  • Immunofluorescence (IF) Staining: Fluorescent tagging was used to visualize KIFC1 localization across the cell cycle stages, from interphase through telophase.
  • LC-MS/MS Proteomics: Liquid Chromatography-Mass Spectrometry identified the specific protein interactome of KIFC1.
  • Subcellular Localization Analysis: Interacting proteins were categorized based on their cellular residence (e.g., cytoplasm, nucleus, membrane).
  • Functional Enrichment: Gene Ontology (GO) and KEGG pathway analyses were performed to identify biological themes associated with KIFC1 interactions.

Mitotic Localization and KIFC1 Dynamics

KIFC1 is highly dynamic during cell division. Immunofluorescence imaging reveals that the protein concentrates at the spindle poles during metaphase and anaphase, facilitating the organization of the mitotic machinery. The current correction rectifies a visual error in the representation of the telophase stage, ensuring the transition from Telophase I to Telophase II is accurately depicted to reflect KIFC1's spatial behavior during the final stages of cytokinesis.

Figure 8A: Immunofluorescence staining showing KIFC1 localization (green) and DAPI-stained DNA (blue) across mitotic stages.

Subcellular Proteomic Mapping

A primary focus of this correction is the re-analysis of the subcellular distribution of KIFC1-interacting proteins. While initial reports suggested a predominantly cytoplasmic role, the corrected data reveals a much more significant nuclear presence.

Figure 8B/C: Quantitative distribution and categorization of KIFC1-interacting proteins by subcellular location.

Key quantitative shifts identified in the correction include:

  • Nucleus: Increased significantly to 35.62% (previously reported as 9.63%).
  • Cytoplasm: Adjusted to 40.52% (from 32.33%).
  • Membrane: Reduced to 11.76% (from 23.69%).

This substantial increase in nuclear localization suggests that KIFC1 may play a more direct role in nuclear structural integrity or gene expression regulation than previously understood.

Functional Hubs and Pathways

Functional analysis via GO and KEGG pathways indicates that KIFC1-interacting proteins are integral to the Spliceosome and Ribosome pathways. These findings suggest that KIFC1 acts as a "master regulator," influencing not only physical cellular transport but also the processing of genetic messages and protein synthesis. These interactions likely drive the tumor proliferation and immune evasion characteristics observed in ccRCC patients with high KIFC1 expression.

Conclusion

The correction of KIFC1’s interactome map emphasizes the protein's multifaceted role in ccRCC. The significant nuclear localization of its partners suggests new avenues for therapeutic intervention. Future research should investigate whether inhibiting KIFC1 can disrupt these nuclear and cytoplasmic hubs, potentially sensitizing tumors to existing immunotherapies or slowing metastatic progression.

Summary updated

Abstract

Due to an error during figure assembly, in Figure 8A two cells in the stage "telophase I" were selected.One exemplary cell has been replaced with a "telophase II" stage cell.
BibTeX
@inproceedings{du2025author,
  author = {Bin Du and Jia Wang and Jinping Zheng and Jing Huo and Pu Wang},
  title = {{Author Correction: Identification of KIFC1 as an independent prognostic marker in renal clear cell carcinoma correlates with tumor proliferation and immune infiltration}},
  booktitle = {Scientific},
  year = {2025},
  doi = {10.1038/s41598-025-87056-x},
}
Figure